Literature DB >> 18767956

DNA vaccination and gene therapy: optimization and delivery for cancer therapy.

Angela M Bodles-Brakhop1, Ruxandra Draghia-Akli.   

Abstract

This review will focus on DNA vaccine approaches for the prevention or treatment of cancer and its complications. DNA vaccine therapies are a relatively novel method of cancer treatment with the goal to induce immunity against tumor-associated antigens. Both viral and nonviral vaccines have been tested in preclinical and clinical models with variable success. However, the development of new delivery methods, such as electroporation, as well as the use of agents that improve antigen uptake or presentation, and the optimization of the transgene sequences, are overcoming historical drawbacks. Efficacy and safety issues of the in vivo use of DNA-based vaccines, as well as data from preclinical and recent clinical studies, are discussed. Novel developments will improve clinical efficacy, with the potential for DNA vaccination to enter in to the arsenal of cancer therapies in the near future.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18767956     DOI: 10.1586/14760584.7.7.1085

Source DB:  PubMed          Journal:  Expert Rev Vaccines        ISSN: 1476-0584            Impact factor:   5.217


  22 in total

1.  Comparative analysis of antigen-targeting sequences used in DNA vaccines.

Authors:  Joana A Carvalho; Adriano R Azzoni; Duarte M F Prazeres; Gabriel A Monteiro
Journal:  Mol Biotechnol       Date:  2010-03       Impact factor: 2.695

2.  Identification of a 17beta-hydroxysteroid dehydrogenase type 12 pseudogene as the source of a highly restricted BALB/c Meth A tumor rejection peptide.

Authors:  Ronald C Hendrickson; Vito R Cicinnati; Andreas Albers; Grzegorz Dworacki; Andrea Gambotto; Ornella Pagliano; Thomas Tüting; Jose I Mayordomo; Carmen Visus; Ettore Appella; Jeffrey Shabanowitz; Donald F Hunt; Albert B DeLeo
Journal:  Cancer Immunol Immunother       Date:  2009-06-27       Impact factor: 6.968

3.  An artificial PAP gene breaks self-tolerance and promotes tumor regression in the TRAMP model for prostate carcinoma.

Authors:  Elmar Spies; Wilfried Reichardt; Gerardo Alvarez; Marcus Groettrup; Peter Ohlschläger
Journal:  Mol Ther       Date:  2011-11-15       Impact factor: 11.454

4.  Hyaluronidase and collagenase increase the transfection efficiency of gene electrotransfer in various murine tumors.

Authors:  Maja Cemazar; Muriel Golzio; Gregor Sersa; Jean-Michel Escoffre; Andrej Coer; Suzana Vidic; Justin Teissie
Journal:  Hum Gene Ther       Date:  2011-09-09       Impact factor: 5.695

5.  Immunogenicity of a novel enhanced consensus DNA vaccine encoding the leptospiral protein LipL45.

Authors:  P Vijayachari; K Vedhagiri; K Mallilankaraman; P P Mathur; N Y Sardesai; D B Weiner; K E Ugen; K Muthumani
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

6.  Electroporation of synthetic DNA antigens offers protection in nonhuman primates challenged with highly pathogenic avian influenza virus.

Authors:  Dominick J Laddy; Jian Yan; Amir S Khan; Hanne Andersen; Amanda Cohn; Jack Greenhouse; Mark Lewis; Jody Manischewitz; Lisa R King; Hana Golding; Ruxandra Draghia-Akli; David B Weiner
Journal:  J Virol       Date:  2009-02-11       Impact factor: 5.103

7.  Numerical optimization of gene electrotransfer into muscle tissue.

Authors:  Anze Zupanic; Selma Corovic; Damijan Miklavcic; Mojca Pavlin
Journal:  Biomed Eng Online       Date:  2010-11-04       Impact factor: 2.819

8.  Translational Approaches towards Cancer Gene Therapy: Hurdles and Hopes.

Authors:  Jaleh Barar; Yadollah Omidi
Journal:  Bioimpacts       Date:  2012-09-22

9.  High dose of plasmid IL-15 inhibits immune responses in an influenza non-human primates immunogenicity model.

Authors:  Jiangmei Yin; Anlan Dai; Dominick J Laddy; Jian Yan; Tatiana Arango; Amir S Khan; Mark G Lewis; Hanne Andersen; Michele A Kutzler; Ruxandra Draghia-Akli; David B Weiner; Jean D Boyer
Journal:  Virology       Date:  2009-08-15       Impact factor: 3.616

10.  Enhancing DNA vaccine potency by co-administration of xenogenic MHC class-I DNA.

Authors:  T H Kang; J-Y Chung; A Monie; S I Pai; C-F Hung; T-C Wu
Journal:  Gene Ther       Date:  2009-11-26       Impact factor: 5.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.